What is hCG?

hCG is human chorionic gonadotropin, a placental glycoprotein hormone that activates the LH/CG receptor. [1][2][3]

Clinically, hCG is used in fertility and reproductive-endocrine contexts such as ovulation triggering and selected hypogonadotropic hypogonadism situations, depending on product label. [1][2][3]

In men, hCG can stimulate Leydig-cell testosterone production, which is why it appears in fertility-preservation and androgen-axis discussions. That does not make it a weight-loss or bodybuilding peptide. [1][2][3]

What hCG is investigated for

hCG evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Ovulation trigger and assisted reproduction

Injectable

82% Strong

Ovulation triggering has the highest-confidence hCG evidence and is separate from unsupported weight-loss claims. [1][5][6]

Human evidence

Pregnyl labeling and gonadotropin literature support hCG for ovulation induction and assisted reproduction contexts. [1][5][6]

Animal / mechanistic evidence

The mechanism is LH-receptor activation to trigger final follicular maturation and ovulation. [1][5][6]

Male hypogonadotropic hypogonadism and fertility

Injectable

70% Moderate

Male reproductive-axis support is human-studied and condition-specific. [1][2][3][10]

Human evidence

Human reviews and label context support hCG in male hypogonadotropic hypogonadism and selected infertility settings. [1][2][3][10]

Animal / mechanistic evidence

The rationale is LH-like Leydig-cell stimulation to support testosterone and spermatogenesis pathways. [1][2][3][10]

Cryptorchidism and delayed puberty in boys

Injectable

66% Moderate

Pediatric use is a distinct clinician-managed label indication, not a general wellness use. [1][5]

Human evidence

Pregnyl labeling includes selected pediatric uses such as prepubertal cryptorchidism not due to obstruction and selected hypogonadotropic hypogonadism contexts. [1][5]

Animal / mechanistic evidence

The pediatric rationale follows gonadotropin activity on testicular endocrine development under specialist care. [1][5]

Testicular function during TRT or AAS suppression

Injectable

56% Emerging

TRT or AAS suppression support is distinct from the unsupported Simeons hCG diet claim and should stay focused on testicular volume, spermatogenesis, and clinician-managed fertility goals. [4][2][11][3]

Human evidence

Male hypogonadism and infertility literature discusses hCG-based approaches for preserving or restoring testicular function in testosterone-suppressed contexts, including TRT and anabolic-androgenic-steroid suppression discussions. [4][2][11][3]

Animal / mechanistic evidence

The mechanism is maintenance of intratesticular LH-like signaling when endogenous gonadotropins are suppressed. [4][2][11][3]

Evidence snapshot

Overall confidence

Strong

82%

hCG has strong support in supervised reproductive-endocrine medicine. Diet, performance, or unsupervised testosterone-adjacent uses are separate and weaker. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

82%

Human evidence

Strong

FDA labeling and reproductive-medicine practice support injectable hCG for specific fertility goals. [1][2][3][4]

34%

Animal / preclinical

Limited

LH/CG receptor activation directly supports ovulation-trigger and gonadal-axis physiology. [1][2][3][4]

82%

Mechanism support

Strong

hCG activates LH/CG receptors in ovaries and testes. It can trigger final oocyte maturation/ovulation or stimulate testicular testosterone production when the axis is responsive. [1][2][3][4]

Forms & administration

hCG is an approved injectable gonadotropin with indication-specific IU dosing. Fertility, cryptorchidism, and male hypogonadotropic-hypogonadism label contexts are separate from casual hormone-support protocols. [1][17]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Pregnyl labeling is indication-specific: ovulation trigger is 5000-10,000 USP units once after gonadotropins; male hypogonadotropic-hypogonadism examples include 500-1000 USP units 3 times weekly initially or 4000 USP units 3 times weekly. [1][17]

Frequency

Frequency is protocol-specific: one-time ovulation trigger, 3-times-weekly male endocrine regimens, or pediatric cryptorchidism regimens. [1][17]

Timing Considerations

Timing is cycle-, lab-, or indication-timed rather than a generic daily supplement schedule. [1][17]

Cycle Length

Pregnyl label examples range from one-time ovulation trigger dosing to 3-week, 6-week, and multi-month male endocrine regimens. [1][17]

What to expect

Same day

Injectable hCG ovulation-trigger use is cycle-timed, with the expected reproductive effect tied to follicle response and clinic confirmation. [1][2][3][4][17]

Weeks to months

Injectable male reproductive-axis protocols may show changes in testosterone, estradiol, testicular response, semen parameters, and symptoms. [1][2][3][4][17]

After stopping

Testosterone and fertility markers may drift toward baseline after injectable hCG stops if the underlying axis problem remains. [1][2][3][4][17]

Safety profile

hCG safety is reproductive-endocrine and indication-specific: injection reactions, headache, mood symptoms, edema, OHSS, gynecomastia, thromboembolism, and sports status matter. [1][2][3][19]

Common side effects

Injection-site reactions [1][2][3][19]
Headache [1][2][3][19]
Mood changes [1][2][3][19]
Edema [1][2][3][19]

Cautions

Ovarian hyperstimulation [1][2][3][19]
Thromboembolism [1][2][3][19]
Gynecomastia / estradiol [1][2][3][19]
Prohibited in males [1][2][3][19]

What we don't know

Non-medical weight-loss, performance, and casual hormone-support use have different risk-benefit profiles from reproductive care. [1][2][3][19]

Who hCG is not for

Route-specific avoid and medical-review notes:

Pregnancy unless part of supervised reproductive care
Pregnancy unless part of supervised reproductive care warrants medical review or avoidance for hCG. [1][2][3]
Hormone-sensitive cancer without specialist review
Hormone-sensitive cancer without specialist review warrants medical review or avoidance for hCG. [1][2][3]
Unexplained uterine bleeding or ovarian cysts without clinician review
Unexplained uterine bleeding or ovarian cyst without clinician review warrants medical review or avoidance for hCG. [1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Gonadotropins / fertility meds
FSH, LH, clomiphene, letrozole, or multi-drug fertility protocols can compound ovarian-stimulation and multiple-gestation risk; this is a route-specific reproductive caution. [1][2][3][19]
Testosterone / estrogen modulators
Testosterone, SERMs, aromatase inhibitors, or estrogen therapy can change testosterone-estradiol response and gynecomastia signals; this is a theoretical pathway caution. [1][2][3][19]
Diuretics during OHSS risk
Diuretics can worsen the intravascular-volume problem in OHSS contexts; this is a route-specific caution. [1][2][3][19]
Performance stacks
Performance stacks that combine hCG with androgens or masking strategies add endocrine and anti-doping risk; this is a theoretical pathway caution. [1][2][3][19]

Regulatory status

United States

In the U.S. as of 2026-06-21, chorionic gonadotropin products have FDA-approved reproductive-endocrine indications. Weight-loss, bodybuilding, and casual hormone-support use are outside those approvals and should not be described as label-backed. [1][17][18][21]

Route	FDA drug approval	503A compounding
Injectable	Approved FDA-approved chorionic gonadotropin products have reproductive-endocrine indications; weight-loss, bodybuilding, or casual hormone-support use is outside those labels. [1][17][17]	Not Listed 503A compounding for hCG is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [1][17][17][18][21][22]

Injectable

FDA drug approval

Approved

FDA-approved chorionic gonadotropin products have reproductive-endocrine indications; weight-loss, bodybuilding, or casual hormone-support use is outside those labels. [1][17][17]

503A compounding

Not Listed

503A compounding for hCG is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [1][17][17][18][21][22]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets. [24][25][26][27]

Sports & competition

WADA S2 prohibits chorionic gonadotropin in males; tested athletes should not treat hCG as athlete-cleared without a valid TUE or anti-doping review. [19][17][18][21][22]

How it works

hCG activates LH/CG receptors in ovaries and testes. In plain terms, injectable hCG can trigger final oocyte maturation or ovulation in fertility care, and it can stimulate testicular testosterone production when Leydig cells remain responsive. [1][2][3][4]

Because hCG acts downstream at the gonad, the mechanism is different from kisspeptin or gonadorelin. Sex, dose, fertility goal, estrogen response, ovarian status, testicular status, and monitoring determine whether the hormone signal is useful or risky. The injectable route also makes ovarian hyperstimulation and androgen effects practical concerns. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about hCG:

A key evidence gap is clearer public separation of reproductive use from diet/performance claims. [1][2][3][4]

A key evidence gap is long-term male fertility-preservation comparisons. [1][2][3][4]

A key evidence gap is product-specific use after exogenous androgen exposure. [1][2][3][4]

Common questions

Is hCG FDA-approved?

Yes. hCG products have FDA-approved reproductive-endocrine indications in the U.S., including specific fertility and hypogonadism contexts. [17][18][1]

Is hCG approved for weight loss?

No. hCG is not FDA-approved for weight loss; weight-loss claims are separate from reproductive-endocrine indications. [17][18][1]

Is hCG the same as gonadorelin?

No. hCG acts at LH/CG receptors downstream; gonadorelin is GnRH upstream at the pituitary. [17][18][1]

Myths & misconceptions

Myth

The hCG diet is an approved hormone protocol.

Reality

hCG approval is reproductive-endocrine, not a weight-loss approval. [1][2][3][4]

Myth

hCG is a simple testosterone booster.

Reality

It changes reproductive hormones and needs lab-guided monitoring. [1][2][3][4]

History & discovery

hCG became a clinical reproductive hormone because its LH-like activity can act directly at gonadal receptors. Its history is fertility and endocrine medicine before wellness or diet-market claims. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]

Injectable hCG became useful for ovulation triggering and reproductive-endocrine contexts because it can mimic LH activity. That established a supervised, indication-specific route history. [1][2][3][4]

Later literature reviewed male hypogonadism and infertility use, while weight-loss and performance claims diverged from labeling. The history therefore separates legitimate endocrine use from misuse. [1][2][3][4]